Patents by Inventor Doris Hubler

Doris Hubler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8338395
    Abstract: Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: December 25, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilheim Kuhnz
  • Patent number: 7718640
    Abstract: The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: May 18, 2010
    Assignee: Bayer-Schering Pharma AG
    Inventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilhelm Kuhnz
  • Publication number: 20090156564
    Abstract: Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.
    Type: Application
    Filed: February 24, 2009
    Publication date: June 18, 2009
    Inventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilheim Kuhnz
  • Publication number: 20070078091
    Abstract: This invention relates to pharmaceutical combinations for compensating for an absolute and relative testosterone deficiency in men with simultaneous prophylaxis for the development of a benign prostatic hyperplasia (BPH) or prostate cancer. The combinations according to the invention contain a natural or synthetic androgen in combination with a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5?-reductase inhibitor, an ?-andreno-receptor blocker or a phosphodiesterase inhibitor. In comparison to the combinations according to the invention, any active ingredient by itself cannot achieve the desired goal.
    Type: Application
    Filed: September 8, 2006
    Publication date: April 5, 2007
    Inventors: Doris Hubler, Michael Oettel, Lothar Sobek, Walter Elger, Abdul-Abbas Al-Mudhaffar
  • Publication number: 20050032762
    Abstract: The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.
    Type: Application
    Filed: March 12, 2004
    Publication date: February 10, 2005
    Inventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilhelm Kuhnz
  • Patent number: 5866559
    Abstract: The 17.alpha.-cyanomethylestra-4,9-diene derivative compounds are of formula I: ##STR1## wherein R.sub.1 is an alkyl group having from 1 to 2 carbon atoms; R.sub.2 is an alkyl group with 1 to 10 carbon atoms, an acyl group with 1 to 10 carbon atoms or a trialkylsilyl group; and R.sub.3 is an oxygen atom or a R--O--N group, wherein R is a hydrogen atom, an acyl group with 1 to 10 carbon atoms, an alkyl group with 1 to 10 carbon atoms, a sulfamoyl group, an alkylsilyl group or a trialkylsilyl group. These compounds, particularly in combination with at least one suitable estrogen, are suitable for treatment of endometrioses or gestagen-dependent tumors and for hormonal contraception and climacteric hormone replacement therapy (HRT). Processes for making the new steroids are described as well as methods of making the pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: February 2, 1999
    Assignee: Jenapharm GmbH
    Inventors: Gerhard Teichmuller, Gerd Muller, Sigfrid Schwarz, Bernd Undeutsch, Harry Henkel, Ronald Gebuhr, Gunter Kaufmann, Doris Hubler, Michael Oettel
  • Patent number: 5855905
    Abstract: A compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases. This invention relates to compound preparations containing biogenous or synthetic androgens and biogenous or synthetic estrogens that are used for the treatment of imbalances of the testosterone metabolism in old age, of hypogonadal men, and of men with hypophyseal diseases. These compound preparations are present in various galenic formulations such as ointments, gels, sprays, TTS systems, tablets, lozenges, capsules, and suppositories. These preparations are used to treat the fluctuations of the testosterone metabolism occurring in old age and with certain diseases such as hypophyseal diseases (adenoma), hypogonadism and/or metabolic syndrome, to maintain the balance between androgens and estrogens found in young and healthy men in ill and/or elderly men as well.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: January 5, 1999
    Assignee: Jenapharm GmbH & Co. KG
    Inventors: Michael Oettel, Siegfried Golbs, Michael Dittgen, Carsten Timpe, Thomas Graser, Doris Hubler
  • Patent number: 5614213
    Abstract: The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: March 25, 1997
    Assignee: EnTec Gesellschaft fuer Endokrinologische Technologie m.b.H.
    Inventors: Walter Elger, Birgitt Schneider, Michael Oettel, Michael Ernst, Doris Hubler, Michael Dittgen